Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

161

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

161 results for “Adipose-derived stem cells”

Learn how ShareScore rates datasets ↗
ClinicalTrials.gov32/100

Autologous Adipose-Derived Adult Stem Cell Transplantation for Corneal Diseases

ClinicalTrials.gov study NCT02932852. IPD Sharing: Not stated. Countries: 1. Publications: 5.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Safety and Efficacy of Autologous Adipose-Derived Stem Cell Transplantation in Type 2 Diabetics

ClinicalTrials.gov study NCT00703612. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Administration of Adipose-derived Stem Cells (ASC) in Patient With Critical Limb Ischemia.

ClinicalTrials.gov study NCT03968198. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Adipose-derived Stem Cell Conditioned Media as a Novel Approach for Hair Regrowth in Male Androgenetic Alopecia

ClinicalTrials.gov study NCT05296863. IPD Sharing: Not stated. Countries: 1. Publications: 31.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Safety and Efficacy Adipose-Derived Stem Cell Injection Partial Thickness Rotator Cuff Tears

ClinicalTrials.gov study NCT02918136. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Safety and Efficacy of Autologous Adipose-Derived Stem Cell Transplantation in Patients With Type 1 Diabetes

ClinicalTrials.gov study NCT00703599. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Clinical Trial Study About Human Adipose-Derived Stem Cells in the Stroke

ClinicalTrials.gov study NCT02813512. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Randomized, Parallel Group, Placebo Control, Unicentric, Interventional Study to Assess the Effect of Expanded Human Allogeneic Adipose-derived Mesenchymal Adult Stem Cells on the Human Response to Li

ClinicalTrials.gov study NCT02328612. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
dryad32/100

Results from: Angiogenic property of silk fibroin scaffolds with adipose-derived stem cells on chick chorioallantoic membrane

Open the record for dataset details and reuse information.

publicSep 2020View details →
zenodo28/100

raw data - circNR3C2 promote chondrogenic differentiation and cartilage repair of human adipose-derived stem cells via hsa-miR-647/SOX9 pathway

Open the record for dataset details and reuse information.

opencc-by-4.0Nov 2024View details →
zenodo28/100

Application of adipose-derived Mesenchymal Stem Cells in an in vivo model of peripheral nerve damage

<p>The aim of this study is to address this issue by performing a detailed analysis of the therapeutic 29 benefits of two treatment options: adipose tissue derived-mesenchymal stem cells (ASCs) and ASC-30 conditioned medium (CM).</p>

opencc-byJul 2022View details →
dryad28/100

Human adipose-derived mesenchymal stem cells prevent type 1 diabetes induced by immune checkpoint blockade

<p class="MsoNormal"><span><strong>Aims/hypothesis</strong></span></p> <p class="MsoNormal"><span> Immunomodulators blocking cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) have improved the treatment of a broad spectrum of cancers. These immune checkpoint inhibitors (ICIs) reactivate the immune system against tumour cells but can also trigger autoimmune side effects, including type 1 diabetes. Mesenchymal stem cell (MSC) therapy is the most prevalent cell therapy, with tissue-regenerating, anti-fibrosis and immunomodulatory functions provided by the secretome of the cells. Here, we examined whether systemic MSC treatment could prevent the development of type 1 diabetes in a NOD mouse model.</span></p> <p class="MsoNormal"><span><strong>Methods</strong> </span></p> <p class="MsoNormal"><span>The purified PD-L1 monoclonal antibody was administered to induce diabetes in male NOD mice which normally do not develop diabetes. Human adipose-derived MSCs were administered by tail vein injections. T cells, macrophages and monocyte-derived macrophages expressing C-X-C motif chemokine ligand 9 (CXCL9) in pancreatic sections of NOD mice and a cancer patient who developed diabetes following the ICI treatments were analysed by immunofluorescence. Tissue localisation of the injected MSCs, plasma exosome levels and plasma cytokine profiles were also investigated.</span></p> <p class="MsoNormal"><span><strong>Results</strong> </span></p> <p class="MsoNormal"><span>PD-1/PD-L1 blockade induced diabetes in 16 of 25 (64%) NOD mice which received anti-PD-L1 mAb without hMSCs [MSC(−)], whereas MSC administration decreased the incidence to four of 21 (19%) NOD mice which received anti-PD-L1 mAb and hMSCs [MSC(+)]. The PD-1/PD-L1 blockade significantly increased the area of CD3-positive T cells (6.2-fold) and Macrophage-2 (Mac-2) antigen (2.5-fold)- and CXCL9 (40.3-fold)-positive macrophages in the islets. MSCs significantly reduced T cell (45%) and CXCL9-positive macrophage (67%) accumulation in the islets and the occurrence of diabetes. The insulin content (1.9-fold) and islet beta cell area (2.7-fold) were also improved by MSCs. T cells and CXCL9-positive macrophages infiltrated into the intricate gaps between the beta cells in the islets by PD-1/PD-L1 blockade. Such immune cell infiltration was largely prevented by MSCs. The most striking difference was observed in the CXCL9-positive macrophages, which normally did not reside in the beta cell region in the islets but abundantly accumulated in this area after PD-1/PD-L1 blockade and were prevented by MSCs. The CXCL9-positive macrophages were also observed in the islets of a cancer patient who developed diabetes following the administration of ICIs but little was observed in a control patient. Mechanistically, the injected MSCs accumulated in the lung but not in the pancreas and strongly increased plasma exosome levels and changed plasma cytokine profiles.</span></p> <p class="MsoNormal"><span><strong>Conclusions/interpretation</strong></span></p> <p class="MsoNormal"><span> Our results suggest that MSCs can prevent the incidence of diabetes associated with immune checkpoint cancer therapy and may be worth further consideration for new adjuvant cell therapy.</span></p> <p class="MsoNormal"><span><strong>Data availability</strong> </span></p> <p class="MsoNormal"><span>All datasets were deposited to DOI https://doi.org/10.5061/dryad.xwdbrv1fh.</span></p>

opencc-zeroJul 2022View details →
zenodo28/100

Application of adipose-derived stem cells combined with platelet-rich plasma in a rat rotator cuff repair model

<p>A controlled experimental study conducted on 48 Sprague-Dawley rats. The supraspinatus tendon was sectioned and repaired and was randomly allocated to two groups: application of PRP alone or PRP and ASCs. Biomechanical and histological analysis was performed at 3 days, 1, 2 and 4 weeks. &nbsp;<br> Results: There were no statistically significant differences in the biomechanical study. In the PRP group, load to failure at two weeks was 3.89 N &plusmn; 0.99 and in the ASCs group was 7.87 N &plusmn; 2.18 (p=0.05). Histological examination showed an increase in the presence of vessels at one and four weeks in the ASCs group (p=0.047). Collagen fibers were present in 25% of the repaired tissue in the ASCs group at one week and absent in the PRP group (p=0.047). Maximum differences in collagen concentration occurred at two weeks in favor of the ASCs group (p=0.059).<br> Conclusion: The use of ASCs does not improve the biomechanical properties of the repair. However, increased vascularity and collagen fibers type I were promising findings in the group treated with ASC.</p>

opencc-by-4.0Feb 2019View details →
ClinicalTrials.gov28/100

Safety and Efficacy of Human Adipose-Derived Stem Cell Exosomes in Acute Ischemic Stroke

ClinicalTrials.gov study NCT07398612. IPD Sharing: YES. Countries: 0. Publications: 30.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov28/100

Clinical Study of Adipose-derived Stem Cells in the Treatment of Diabetic Foot

ClinicalTrials.gov study NCT03916211. IPD Sharing: Not stated. Countries: 0. Publications: 14.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

Autologous Keratinocyte Suspension Versus Adipose-Derived Stem Cell-Keratinocyte Suspension for Post-Burn Raw Area

ClinicalTrials.gov study NCT03686449. IPD Sharing: NO. Countries: 0. Publications: 14.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov28/100

The Clinical Application of Adipose-Derived Stem Cells on Facial Rejuvenation

ClinicalTrials.gov study NCT02923219. IPD Sharing: UNDECIDED. Countries: 0. Publications: 8.

restrictedIPD-UNDECIDEDFeb 2026View details →
dryad28/100

Human adipose-derived mesenchymal stem cells prevent type 1 diabetes induced by immune checkpoint blockade

Open the record for dataset details and reuse information.

publicJul 2022View details →
geo24/100

Effect of exogenous FABP4 (A-FABP/aP2) and FABP5 (E-FABP/mal1) on gene expression in adipose-derived stem cells (ADSC) and 233A cells

GEO Series GSE83587. Homo sapiens. 6 samples. Type: Expression profiling by array.

openGEO-OpenJun 2016View details →
geo24/100

Multi-omics analysis to examine gene expression and metabolites from multisite adipose-derived mesenchymal stem cells

GEO Series GSE161312. Rattus norvegicus. 9 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenMar 2021View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record